Improving dystrophin function for treating Duchenne muscular dystrophy
Official title: Expression of dystrophins with enhanced function
Funded at University of Washington · NIH-11048058 · Data updated 2026-11-12
This study is working on new ways to help people with Duchenne muscular dystrophy (DMD) by improving a key protein that helps muscles work better, using special tools to deliver these improvements directly to the muscles while aiming to make treatments safer and more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | January 22, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $671,240 |
| NIH project number | 1R01AR082814-01A1 |
| Project ID | NIH-11048058 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy, particularly those with specific genetic mutations affecting dystrophin.
✕Less likely to help
Patients with forms of muscular dystrophy other than Duchenne muscular dystrophy may not benefit from this research.
What this research studies
This research focuses on developing enhanced versions of dystrophin, a protein crucial for muscle function, to treat Duchenne muscular dystrophy (DMD), a severe genetic disorder. The approach involves using adeno-associated viral (AAV) vectors to deliver micro-dystrophins to muscle tissues, aiming to improve their effectiveness and reduce side effects compared to existing therapies. The study also explores the use of anti-sense oligonucleotides to skip faulty parts of the dystrophin gene, potentially allowing for more efficient gene therapy. By addressing the complexities of DMD mutations, this research seeks to provide a more effective treatment option for patients suffering from this condition.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with Duchenne muscular dystrophy, improving their muscle function and quality of life.
How similar studies have gone: Previous studies have shown promise with similar gene therapy approaches, including the use of micro-dystrophins and anti-sense oligonucleotides, with some therapies already receiving FDA approval.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Chamberlain, Jeffrey S — University of Washington
- Study coordinator: Chamberlain, Jeffrey S
Related research
Other NIH-funded projects on the same topics.
-
Making genetic testing more accessible to the public
This study is all about making it easier for people at risk of certain cancers, like breast, ovarian, and colon cancers, to get genetic testing, so we can find out what helps them access these important services and understand how they can benefit from them.
-
Breast cancer diagnosis in low-resource settings using millifluidics and fast digital imaging in Ghana
A new project will test a fast, low-cost way to diagnose breast cancer at the point of care in Ghana using small-batch fluidics and direct digital imaging.
-
Binaural Hearing and Speech in Noise in Children
This project explores how children hear speech in noisy classrooms using how the two ears work together to see if binaural processing differences explain why some kids struggle more than others.
-
Neural circuits that control pain aversion in the brain
Researchers are exploring how a specific brain area helps people feel and avoid pain, with potential to lead to better pain treatments.
-
United World Antiviral Research Network (UWARN)
A collaborative, international effort is testing new virus surveillance and evolution ideas to help people living with HIV and communities in LMICs stay safer from current and emerging viruses.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.